Gam-COVID-Vac

COVID-19

Two-dose, heterologous recombinant adenovirus vaccine

Development status

  1. Emergency use/conditional marketing authorizations granted in multiple countries
  2. Phase 3 clinical trials underway in Belarus, the United Arab Emirates, Venezuela and India
15 active deals

Emergency use
authorizations granted in:

Drugs to Watch - Gam-COVID-Vac Placeholder
Drugs to Watch - Gam-COVID-Vac

Distribution

The vaccine is well-tolerated and easily administered.

With a reported 91.6% efficacy when administered per protocol but it does require storage at freezer temperatures.

Drugs to Watch 2021

Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch
Drugs to Watch

From innovation to bottom line

Access our global intelligence, advanced analytics and global team of experts.

Contact our team